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We report in vitro and in vivo magnetic resonance (MR) imaging of C6 glioma cells with a novel acetylated
3-aminopropyltrimethoxysilane (APTS)-coated iron oxide nanoparticles (Fe3O4 NPs). In the present study,
APTS-coated Fe3O4 NPs were formed via a one-step hydrothermal approach and then chemically modified with
acetic anhydride to generate surface charge-neutralized NPs. Prussian blue staining and transmission electron
microscopy (TEM) data showed that acetylated APTS-coated Fe3O4 NPs can be taken up by cells. Combined
morphological observation, cell viability, and flow cytometric analysis of the cell cycle indicated that the acetylated
APTS-coated Fe3O4 NPs did not significantly affect cell morphology, viability, or cell cycle, indicating their good
biocompatibility. Finally, the acetylated APTS-coated Fe3O4 nanoparticles were used in magnetic resonance imaging
of C6 glioma. Our results showed that the developed acetylated APTS-coated Fe3O4 NPs can be used as an effective
labeling agent to detect C6 glioma cells in vitro and in vivo for MR imaging. The results from the present study
indicate that the developed acetylated APTS-coated Fe3O4 NPs have a potential application in MR imaging.
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GliomaBackground
The molecular imaging (MI) of tumors has recently
gained widespread use [1-4] due to its ability to facilitate
quantitative and repetitive imaging of targeted mole-
cules and biological processes in living organisms [2,5,6].
Contrast agents are generally required for high-quality MI
diagnosis. Advances in nanotechnology enable the devel-
opment of various nanoparticles (NPs) as contrast agents
for effective MI in the diagnosis or analysis of diseases.
Superparamagnetic iron oxide nanoparticles (SPIONs) are
a promising form of imaging probe that can accumulated
in cells and generate a strong magnetic resonance (MR)
imaging contrast in T2- or T2*-weighted images [7]. To* Correspondence: kangan.li@shsmu.edu.cn; mingwu_shen@yahoo.com;
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in any medium, provided the original work is pdate, SPIONs have been used to investigate several patho-
physiological processes in tumor cells [8,9], transplanted
cells [1,7,10], or precursor cells in vivo [11-13].
SPION probes are generally comprised of superpara-
magnetic iron oxide cores of magnetite or maghemite NPs
encased in various coatings. Cellular uptake of SPIONs
may be achieved by phagocytosis, macropinocytosis, or
receptor-mediated endocytosis [2,14,15]. For effective MR
imaging applications, synthesizing SPIONs with control-
lable sizes and surface functionalities is important, given
that the in vivo biomedical performance, especially the
opsonization, pharmacokinetics, and biodistribution, of
the SPIONs can be directly impacted by the particle's size
and surface modifications [16]. Various methods have
been employed to synthesize SPIONs with controllable
size, such as controlled co-precipitation of Fe(II) and
Fe(III) ions at an elevated temperature [17], successive
reduction-oxidation process in a reverse micelle system
[18], thermal decomposition [19], and a hydrothermal
method under higher pressures [20]. To make SPIONsen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ity for biomedical applications, surfactant molecules
[21,22], silane agents [23-25] or other small molecular
ligands [9,26-28], polyethylene glycol (PEG) derivatives
[29,30], and dendrimers [15,31,32] have been used to
modify SPIONs using either in situ modifications or post-
modification approaches.
In our previous work, we adopted a simple one-step
3-aminopropyltrimethoxysilane (APTS)-assisted hydro-
thermal approach to synthesize APTS-coated Fe3O4 NPs
with reactive surface amine groups [33]. The APTS mo-
dification endowed Fe3O4 NPs with an excellent water
dispersibility and colloidal stability. Additionally, these
APTS-coated Fe3O4 NPs can be further functionalized
with acetyl groups with neutral surface potential following
the reaction of the surface APTS amines with acetic an-
hydride. Our results suggest that the presence of APTS
molecules not only enables efficient APTS coating of the
particles with reactive amine groups but also significantly
limits the particle growth. This prior success led us to
hypothesize that acetylated APTS-coated Fe3O4 NPs may
serve as a labeling agent for MR imaging of cancer cells
both in vitro and in vivo.
In the present study, we synthesized acetylated APTS-
coated Fe3O4 NPs with a mean diameter of 6.5 nm, simi-
lar to our previous report [33]. The formed acetylated
APTS-coated Fe3O4 NPs were used as a labeling agent
for in vitro and in vivo MR imaging of C6 glioma cells.
The cellular uptake of the acetylated APTS-coated
Fe3O4 NPs was confirmed by Prussian blue staining and
transmission electron microscopy (TEM) imaging. Com-
bined morphological observation of the cells, a 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay of cell viability, and flow cytometric analysis of the
cell cycle were used to evaluate the cytotoxicity of the
acetylated APTS-coated Fe3O4 NPs.
Methods
Materials
Ferrous chloride tetrahydrate (FeCl2 · 4H2O >99%), am-
monia (28% to 30% NH3 in aqueous solution), triethyla-
mine, acetic anhydride, and dimethyl sulfoxide (DMSO)
were purchased from Sinopharm Chemical Reagent Co.,
Ltd (Shanghai, China). The APTS and acetic anhydride
were from Acros Organics (Geel, Belgium). C6 glioma
cells (a rat C6 glioma cell line) were purchased from the
Institute of Biochemistry and Cell Biology at the Chinese
Academy of Sciences (Shanghai, China). RPMI 1640
medium, fetal bovine serum (FBS), penicillin, and
streptomycin were purchased from Hangzhou Jinuo
Biomedical Technology (Hangzhou, China). The MTT
was acquired from Shanghai Sangon Biological Engin-
eering Technology and Services Co., Ltd (Shanghai,
China). The water that was used in all of the experimentswas purified using a Milli-Q Plus 185 water purification
system (Millipore, Bedford, MA, USA) with a resistivity
that was higher than 18.2 MΩ cm.
The synthesis of acetylated APTS-coated Fe3O4 NPs
APTS-coated Fe3O4 NPs were synthesized using a hy-
drothermal approach, which was described in our pre-
vious study [20,33]. Typically, FeCl2 · 4H2O (1.25 g) was
dissolved in 7.75 mL water. Under vigorous stirring, am-
monium hydroxide (6.25 mL) was added, and the sus-
pension was continuously stirred in air for 10 min. Next,
2.5 mL APTS was added, and the reaction mixture was
autoclaved (KH-50 Autoclave, Shanghai Yuying Instru-
ment Co., Ltd., Shanghai, China) in a sealed pressure
vessel with a volume of 50 mL at 134°C. After 3 h, the
reaction mixture was cooled to room temperature. The
black precipitate was collected and purified with water
five times and with ethanol twice via a centrifugation-
dispersion process (5,000 rpm, 10 min) to remove excess
reactants. Lastly, the obtained APTS-coated Fe3O4 NPs
were dispersed in ethanol.
The amine groups on the surface of the APTS-coated
Fe3O4 NPs were further acetylated via a reaction with
acetic anhydride, following the protocols described in
our previous study [33]. Briefly, 1 mL of triethylamine
was added to the APTS-coated Fe3O4 NPs (6 mg) solu-
tion that was dispersed in ethanol (5 mL), and the solu-
tion was thoroughly mixed. A DMSO solution (5 mL)
that contained acetic anhydride (1 mL) was added drop-
wise into the solution of APTS-coated Fe3O4 NPs, which
was mixed with triethylamine while being stirred vigor-
ously. The mixture was allowed to react for 24 h. The
DMSO, excess reactants, and by-products were removed
from the mixture by a centrifugation/washing/dispersion
step that was repeated five times to obtain acetylated
APTS-coated Fe3O4 NPs dispersed in water.
Characterization techniques
The morphology of the formed acetylated APTS-coated
Fe3O4 NPs was observed by TEM imaging using a JEOL
2010 F analytical electron microscope (Akishima-shi,
Japan) that operated at 200 kV. The TEM sample was
prepared by placing one drop of diluted suspension of
acetylated APTS-coated Fe3O4 NPs (5 μL) onto a 200-
mesh carbon-coated copper grid and air-dried prior to
measurement. The size of the NPs was measured using
ImageJ 1.40G image analysis software (http://rsb.info.
nih.gov/ij/download.html). A minimum of 200 randomly
selected NPs in different TEM images were analyzed for
each sample to acquire the size distribution histogram.
The transverse relaxometry was performed using a
Signa HDxt 3.0 T superconductor magnetic resonance
system (GE Medical Systems, Milwaukee, WI, USA) with
a wrist receiver coil. For the MR transverse relaxometry
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(1 mL) that were dispersed in water at different con-
centrations were separately added to 1.5-mL Eppendorf
tubes. The transverse relaxation times (T2) were mea-
sured using a multi-echo fast spin echo (MFSE) sequence.
A total of eight echoes were used with the following pa-
rameters: repetition time (TR) = 500 ms, echo time (TE) =
21.9 ms, flip angle = 90°, resolution = 256 × 256, section
thickness = 2 mm, and field of view (FOV) = 80 × 80 mm.
The R2 mapping was performed using a workstation run-
ning Functool 4.5.3 (GE Medical Systems, Milwaukee, WI,
USA). The transverse relaxivities (R2, 1/T2) were deter-
mined using a linear fit of 1/T2 as a function of the Fe
concentration of the particles. The Fe concentration of the
acetylated APTS-coated Fe3O4 NPs was analyzed using
Prodigy inductively coupled plasma-atomic emission spec-
troscopy (ICP-AES) (Teledyne Leeman Labs, Hudson,
NH, USA) following aqua regia treatment.
Cytotoxicity of acetylated APTS-coated Fe3O4 NPs
The C6 glioma cells were continuously grown in a 50-mL
culture flask in regular RPMI 1640 medium that was sup-
plemented with 10% heat-inactivated FBS, 100 U/mL
penicillin, and 100 U/mL streptomycin. A 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was used to quantify the viability of the cells upon
treatment with the acetylated APTS-coated Fe3O4 NPs.
Briefly, 1 × 104 C6 glioma cells per well were seeded into a
96-well plate. Following overnight incubation to bring
the cells to confluence, the medium was replaced with
fresh medium that contained the acetylated APTS-coated
Fe3O4 NPs at different concentrations (0, 1, 10, 25, 50,
and 100 μg/mL). After 24 h of incubation at 37°C, the
metabolically active cells were subsequently detected by
adding MTT to each well. The assays were performed
according to the manufacturer's instructions, and the
absorbance of each well was measured using a Thermo
Scientific Multiskan MK3 ELISA reader (Thermo Scien-
tific, Waltham, MA, USA) at 570 nm. The mean and the
standard error mean (SEM) for the triplicate wells were
reported and normalized. One-way analysis of variance
(ANOVA) statistical analyses were performed to detect
the difference between the cells that were incubated
with different concentrations of acetylated APTS-coated
Fe3O4 NPs and the control cells, which were treated with
phosphate-buffered saline (PBS) buffer. The statistical sig-
nificance level was set to 0.05.
The cytotoxicity of the acetylated APTS-coated Fe3O4
NPs was further examined using flow cytometric analysis
of the cell cycle and apoptosis [34]. C6 glioma cells were
seeded in six-well cell culture plates at a density of 3 ×
105 cells per well in quadruplet and were allowed to grow
to confluence for 24 h. Next, after replacing the medium
with fresh medium that contained different concentrationsof acetylated APTS-coated Fe3O4 NPs (0, 50, and
100 μg/mL), the cells were incubated for 4 h at 37°C
in a CO2 incubator. Following the treatment, the cells
were harvested by trypsinization and centrifugation,
washed with PBS buffer, and fixed in citrate buffer for
2 h. The cells were later centrifuged to remove the citrate
buffer and resuspended with PBS buffer with a cell con-
centration of 1 × 106 cells/mL. The cell suspensions were
incubated with trypsinogen for 3 min and then incu-
bated with RNase for 3 min. Subsequently, the cells
were stained with propidium iodide (PI) for 15 min,
and the PI-stained cells were then counted using flow
cytometry (FACSCalibur, Becton Dickinson, Franklin
Lakes, NJ, USA) in the red (FL2) channel at 488 nm.
The cell cycle profiles, including the G1, G2, and S, phases,
and sub-G1 fractions were analyzed using CellQuest soft-
ware (FACSCalibur, Becton Dickinson, Franklin Lakes,
NJ, USA).
Cellular uptake of acetylated APTS-coated Fe3O4 NPs
The cellular uptake of the acetylated APTS-coated Fe3O4
NPs was primarily evaluated by Prussian blue staining.
The C6 glioma cells were plated in 12-well cell culture
plates at a density of 5 × 105 cells per well in RPMI 1640
medium with 10% FBS for 24 h. Following this step, the
acetylated APTS-coated Fe3O4 NPs were added to each
well at different concentrations (0, 10, 25, and 50 μg/mL)
and incubated for 4 h at 37°C. Next, the cells were stained
with Pearl's Prussian blue solution. First, the samples were
treated with 4% paraformaldehyde for 10 min and were
subsequently washed with Tris-NaCl buffer. The samples
were subsequently exposed to Pearl's solution for 30 min
before being washed with water. After that, the samples
were plated onto sterile coverslips prior to microscopic
imaging. The cell morphology with Prussian blue staining
was observed by optical microscopy (IX71-F22FL/PH,
Olympus Corp., Tokyo, Japan). The magnification was
set at × 200 for all of the samples.
The cellular uptake of acetylated APTS-coated Fe3O4
NPs was further observed by TEM imaging. The C6 gli-
oma cells were plated in six-well cell culture plates at a
density of 3 × 105 cells per well in RPMI 1640 medium
with 10% FBS for 24 h. These cells were allowed to grow
to approximately 80% confluence. Next, the acetylated
APTS-coated Fe3O4 NPs were added to each well at a
final concentration of 25 μg/mL and incubated for 24 h
at 37°C. The culture medium was discarded, and the cells
were washed with PBS buffer, trypsinized, centrifuged,
washed three times with PBS buffer, and fixed with 2.5%
glutaraldehyde in 0.2 M phosphate buffer (pH 7.2) for
12 h at 4°C. The cells were then post-fixed with 1% OsO4
in 0.2 M phosphate buffer (pH 7.2) for 2 h at 4°C. After
additional washes in buffer, the cells were dehydrated and
embedded with Epon 812 (Shell Chemical, UK), followed
Figure 1 TEM micrograph (a) and size distribution histogram (b) of acetylated APTS-coated Fe3O4 NPs.
Figure 2 Transverse relaxation rate (R2, 1/T2) for acetylated
APTS-coated Fe3O4 NPs as a function of Fe concentration.
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tioned using a Reichert-Jung Ultramicrotome (Vienna,
Austria). The sections with a thickness of 75 nm were
mounted onto 200-mesh copper grids and counterstained
with uranyl acetate and lead citrate for 5 min, respectively,
prior to the TEM measurements. The grids were visua-
lized using an H600 transmission electron microscope
(Hitachi, Chiyoda-ku, Japan) with an operating voltage
of 60 kV.
The intracellular uptake of APTS-coated Fe3O4 NPs in
the C6 glioma cells was quantified using a Prodigy ICP-
AES system (Teledyne Leeman Labs, Hudson, NH, USA).
For ICP-AES analysis, 1 × 106 cells were seeded onto a
six-well cell culture plate for 24 h. The cells were then
incubated with different concentrations of acetylated
APTS-coated Fe3O4 NPs (0, 10, 25, 50, and 100 μg/mL)
for 24 h. The cells were washed with PBS buffer three
times, trypsinized, and harvested by centrifugation. The
digestion of the cells was performed in aqua regia, and
the amount of iron uptake in the cells was then quanti-
fied using ICP-AES.
In vitro MR imaging of C6 glioma cells
C6 glioma cells were cultured in 10 mL RPMI 1640 that
was supplemented with 10% FBS on cell culture discs,
and the medium was changed every 24 to 48 h. The cells
were maintained at 37°C in a humidified atmosphere
with 5% CO2 in air. The cells were labeled with acety-
lated APTS-coated Fe3O4 NPs at different concentra-
tions (10, 25, or 50 μg/mL, respectively). Next, 1 × 106
labeled cells were placed into 1.5-mL Eppendorf tubes
supplemented with 1 mL 1% agarose gel. An Eppendorf
tube filled with 1 mL 1% agarose gel was used as a con-
trol. All of the cell phantom MR studies were performed
using a Signa HDxt 3.0 T superconductor magnetic reson-
ance system (GE Medical Systems, Milwaukee, WI, USA).
An axial scan was performed using an eight-channel arrayhead coil. R2 mapping was performed using the MFSE
sequence, with a total of eight echoes and the follow-
ing parameters: TR = 500 ms, TE = 21.9 ms, flip angle =
90°, resolution = 256 × 256, section thickness = 2 mm, and
FOV = 80 × 80 mm. The R2 mapping reconstruction was
performed by two imaging experts on a workstation run-
ning Functool 4.5.3 (GE Medical Systems, Milwaukee, WI,
USA). The R2 values were calculated and recorded as the
mean ± standard deviation (n = 3).
In vivo MR imaging
Animal experiments were designed in compliance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals, and the animal protocol was
approved by the Institutional Animal Care and Use Com-
mittee of Shanghai First People's Hospital (Approval ID
2012-115). Sprague Dawley (SD) rats (Shanghai Slac La-
boratory Animal Center, Shanghai, China) underwent
Figure 3 MTT assay of C6 glioma cell viability following
treatment with acetylated APTS-coated Fe3O4 NPs for 24 h. The
mean and the SEM for the triplicate wells are reported. The data are
expressed as the mean ± SEM.
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beled with acetylated APTS-coated Fe3O4 NPs as per the
following protocol. Briefly, the C6 glioma cells were cul-
tured in RPMI 1640 that was supplemented with 10% FBS
on cell culture discs and which were maintained at 37°C
in a humidified atmosphere with 5% CO2 in air. The
medium was changed every 24 to 48 h. Prior to implan-
tation surgery, the acetylated APTS-coated Fe3O4 NPs
were added into the cell culture dish at a final concentra-
tion of 25 μg/mL for an incubation of approximately 4 h.
Next, the culture medium was discarded, and the cells
were trypsinized, centrifuged, and washed three times with
PBS buffer. In the control group, the C6 glioma cells were
incubated with PBS buffer for 4 h. The SD rats were anes-
thetized with 1% isobarbital (3 mL/kg of body weight)
delivered intraperitoneally. A sphenotresia was then per-
formed using a stereotaxic apparatus (Gene&I, Beijing,
China). One million C6 glioma cells (10 μL) that were la-
beled with the acetylated APTS-coated Fe3O4 NPs were
injected within 10 min into the left frontal lobes of one rat
(n = 12). In the control group, 1 × 106 unlabeled C6 glioma
cells were injected at a rate of 1 μL/min for 10 min into
the left frontal lobe of six rats. The MR imaging (MRI)
scans of the rats were performed at 7, 14, 21, andTable 1 Apoptosis and cell cycle analysis of C6 glioma cells fo
Group Apoptosis (%)
G1
Control 2.39 ± 0.14 27.32 ± 0.45
50 μg/mL 2.38 ± 0.29 27.22 ± 0.43
100 μg/mL 2.40 ± 0.33 27.38 ± 0.52
Mean ± standard deviation, n = 4.28 days post-injection using a Signa HDxt 3.0 T supercon-
ductor magnetic resonance system (GE Medical Systems,
Milwaukee, WI, USA). An axial scan was performed using
a custom-built rodent receiver coil (Chenguang Med
Tech, Shanghai, China). The following parameters were
used for the T2-weighted images: SE/2D sequence, TR =
2,500 ms, TE = 81.9 ms, resolution = 256 × 128, section
thickness = 2.4 mm, and FOV = 80 × 80 mm. The R2 map-
ping was performed using a MFSE sequence, with a total
of eight echoes and the following parameters: TR =
500 ms, TE = 21.9 ms, flip angle = 90°, resolution = 256 ×
256, section thickness = 2 mm, and FOV = 80 × 80 mm.
The R2 mapping reconstruction was performed by two
imaging experts on a workstation running Functool 4.5.3
(GE Medical Systems, Milwaukee, WI, USA). The R2
values in the tumor area were calculated and recorded as
the mean ± standard deviation (n = 3) and analyzed using
a two-tailed, time-dependent, paired t test.Histology study
Following the final MRI scan, each rat was deeply anes-
thetized, and the tumor was resected. The tumor tissues
were post-fixed with 4% paraformaldehyde in a 0.1 M
phosphate buffer (PB; pH 7.4) for 24 h. The samples
were then dehydrated, embedded, and sectioned into
4-μm-thick slices. After dewaxing and rehydration, the
tumor sections were stained with Pearl's Prussian blue so-
lution and hematoxylin and eosin, following the manufac-
turer's instructions.Results and discussion
The synthesis and characterization of acetylated
APTS-coated Fe3O4 NPs
We obtained acetylated APTS-coated Fe3O4 NPs using
the same experimental protocol as was described in our
previous report [33]. TEM was utilized to characterize the
synthesized acetylated APTS-coated Fe3O4 NPs (Figure 1).
The TEM micrograph indicates that the particles have a
spherical or quasi-spherical shape with a mean diameter
of 6.5 ± 1.5 nm, in agreement with our previous results
[33]. The acetylated APTS-coated Fe3O4 NPs in a powder
form can be dissolved in water, PBS, or cell culture me-
dium with good colloidal stability following storage in
4°C for a minimum of 1 month. Generally, the acetylatedllowing incubation with Fe3O4 NPs for 4 h
Cell cycle (%)
G2 S G2/G1
19.42 ± 0.07 53.27 ± 0.33 1.93 ± 0.01
18.74 ± 0.12 54.05 ± 0.39 1.93 ± 0.02
18.64 ± 0.13 55.02 ± 0.41 1.93 ± 0.01
Figure 4 Flow cytometry analysis. Flow cytometry analysis of C6 glioma cells that were treated with the acetylated APTS-coated Fe3O4 NPs at
concentrations of (a) 50 μg/mL and (b) 100 μg/mL for 4 h at 37°C (n = 4). The data of the untreated negative control cells is shown in (c). Red,
G1 phase; blue, S phase; green, G2 phase.
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form before use.
Transverse relaxivity of acetylated APTS-coated Fe3O4 NPs
The magnetic behavior of Fe3O4-based NPs is very im-
portant for their biomedical applications. The transverse
relaxation time (T2) of the NPs was measured to evaluate
the possibility of using acetylated APTS-coated Fe3O4
NPs as a potential T2-based contrast agent for MR im-
aging. The measured T2 data were used to calculate the
transverse relaxivity (R2) (the transverse relaxation rate
per millimolar of iron), which represents the efficiency of
NPs as a T2 contrast agent. As is shown in Figure 2,
the transverse relaxation rate (R2 = 81.5 mM
−1 s−1) as aFigure 5 Optical microscopic images of C6 glioma cells. Prussian blue
and those that were treated with acetylated APTS-coated Fe3O4 NPs at a c
(scale bar = 100 μm).function of the Fe concentration indicates that the relax-
ation rate increases linearly with the Fe concentration with
a slope that is larger than that of Fe3O4 NPs coated with
polymer multilayers (R2 = 78.8 mM
−1 s−1) [31]. Our results
suggest that acetylated APTS-coated Fe3O4 NPs may be
used as a T2-shortening agent, due to their small size and
relatively large R2 value.
The cytotoxicity of acetylated APTS-coated Fe3O4 NPs
The MTT assay was used to assess the viability of C6 gli-
oma cells that were treated with acetylated APTS-coated
Fe3O4 NPs (Figure 3). Compared to the PBS control,
there was no statistically significant difference in the via-
bility of cells that were treated with the particles at astaining of C6 glioma cells that were treated with PBS buffer (a)
oncentration of 10 μg/mL (b), 25 μg/mL (c), and 50 μg/mL (d)
Figure 6 TEM images. TEM images of C6 glioma cells that were incubated with the acetylated APTS-coated Fe3O4 NPs at a concentration of
25 μg/mL for 24 h (a) and C6 glioma cells that were treated with PBS buffer (b). The acetylated APTS-coated Fe3O4 NPs in the endosomes are
visible as electron-dense nanoparticles and are indicated by black arrows. The white arrows indicate the normal endosome without NPs.
Figure 7 Intracellular uptake. The intracellular uptake of acetylated
APTS-coated Fe3O4 NPs quantified using ICP-AES after the C6 glioma
cells were treated with the particles at different concentrations
for 24 h.
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gesting that the acetylated APTS-coated Fe3O4 NPs are
noncytotoxic at the given concentration range.
Cell cycle damage is one of the most important fea-
tures of cytotoxicity [35]. The cell phase distribution is
generally analyzed by the determination of DNA con-
tent, and the fraction of DNA content in the sub-G1
phase is an indicator of apoptosis [36,37]. To investigate
further the influence of the acetylated APTS-coated
Fe3O4 NPs on apoptosis, the treated cells were analyzed
using flow cytometry. The sub-G1 fraction of C6 glioma
cells that were incubated with acetylated APTS-coated
Fe3O4 NPs at concentrations of 50 and 100 μg/mL
were determined to be 2.38% ± 0.29% and 2.40% ± 0.33%
(Table 1), respectively, with no statistically significant
difference compared to the PBS-treated control cells
(2.39% ± 0.14%, p > 0.05). This result also demonstrates
that acetylated APTS-coated Fe3O4 NPs have no effect on
the cell cycle of C6 glioma cells (Figure 4, Table 1).
The in vitro cellular uptake of acetylated APTS-coated
Fe3O4 NPs
To determine the cellular uptake of the APTS-coated
Fe3O4 NPs, the C6 glioma cells that were incubated with
the particles for 24 h were stained with Prussian blue
and imaged with optical microscopy (Figure 5). The C6
glioma cells that were labeled with higher concentrations
(25 and 50 μg/mL) clearly exhibited deeper blue staining
than either those that were labeled using a less concen-
trated particle solution (10 μg/mL) or untreated control
cells, indicating the higher intracellular uptake of the
Fe3O4 NPs. Moreover, the Prussian blue staining data
also indicate that the incubation of the acetylated APTS-
coated Fe3O4 NPs at a concentration as high as 50 μg/mL
does not markedly affect the regular spindle-shaped
cell morphology when compared to the PBS control;
this result is in agreement with the MTT cell viabil-
ity assay data.The C6 glioma cells that were treated with the ace-
tylated APTS-coated Fe3O4 NPs were also imaged by
TEM to identify the uptake of the particles (Figure 6).
Numerous electron-dense particles can be observed in
the cytoplasm of the C6 glioma cells following incuba-
tion with acetylated APTS-coated Fe3O4 NPs for 24 h.
In contrast, control cells that were not treated with the
NPs do not exhibit such high electron-dense particles.
The TEM studies suggest that acetylated APTS-coated
Fe3O4 NPs are able to be taken up by the C6 glioma
cells.
The cellular uptake of acetylated APTS-coated Fe3O4
NPs was further quantified using ICP-AES (Figure 7). It
is clear that iron uptake in C6 glioma cells increases ap-
proximately linearly with the particle concentration. The
ICP-AES data corroborate the Prussian blue staining re-
sults. Overall, the Prussian blue staining, TEM imaging,
and ICP-AES results together confirmed the intracellular
Figure 8 R2 mapping and R2 values of the C6 glioma cell phantoms. (a) R2 mapping of gel phantoms containing C6 glioma cells that were
treated with PBS buffer (1) or with acetylated APTS-coated Fe3O4 NPs at concentrations of 10 μg/mL (2), 25 μg/mL (3), and 50 μg/mL (4). (b) R2
values of the C6 glioma cells with the above treatments.
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is essential for them to be used for cancer cell imaging.
The in vitro MR detection of C6 glioma cells
To conclusively demonstrate our hypothesis that acety-
lated APTS-coated Fe3O4 NPs can be used as an effect-
ive molecular imaging labeling agent via MR imaging,
C6 glioma cells that were treated with different concen-
trations of NPs (0, 10, 25, and 50 μg/mL, respectively)
were imaged using a 3.0-T MR imaging system (Figure 8).
The transverse MR images of C6 glioma cells that wereFigure 9 MR imaging of C6 glioma xenograft tumor model. T2-weight
25 μg/mL acetylated APTS-coated Fe3O4 NPs at (a) 7 days, (b) 14 days, (c)
that were labeled with 25 μg/mL acetylated APTS-coated Fe3O4 NPs at 14
xenografts without labeling at 14 days as a control. (h) A pseudocolor phoincubated with the acetylated APTS-coated Fe3O4 NPs
reveal that the cells gradually become darker with increas-
ing particle concentrations (Figure 8a). A further quantita-
tive analysis of the transverse relaxivities (R2, 1/T2) of the
cells (Figure 8b) indicated that the R2 of C6 glioma cells
that were incubated with the acetylated APTS-coated
Fe3O4 NPs at a concentration of 100 μg/mL was signifi-
cantly higher than those of the cells that were incubated
with lower concentrations of particles (10 and 25 μg/mL)
and that of the negative control cells (p < 0.05). These re-
sults suggest that acetylated APTS-coated Fe3O4 NPs thated MR images of C6 glioma xenografts that were labeled with
21 days, and (d) 28 days. (e) The R2 mapping of C6 glioma xenografts
days. (f) A pseudocolor picture of (e). (g) The R2 mapping of C6 glioma
to of (g). The white arrows indicate the glioma xenografts.
Figure 10 R2 values of C6 glioma xenografts labeled with
25 μg/mL Fe3O4 NPs at 7, 14, 21, and 28 days. The R2 value of C6
glioma xenografts that were treated with PBS buffer after 14 days
was used as a control value.
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intensity of the cells, thereby enabling effective MR detec-
tion of cancer cells in vitro.
In vivo MR imaging of xenografted C6 glioma tumor
model
The excellent in vitro performance of the acetylated
APTS-coated Fe3O4 NPs for C6 glioma cell MR imaging
in addition to the excellent biocompatibility of the parti-
cles encouraged us to pursue the applicability of these
NPs for the in vivo MR imaging study in SD rats. Figure 9
clearly illustrates that the C6 glioma cells that were labeled
with the acetylated APTS-coated Fe3O4 NPs exhibited a
clear contrast in the tumor area, with a significantly lower
signal intensity when compared to unlabeled C6 glioma
cells. Moreover, following analyses at different time points,
we determined that the R2 value of the tumor area labeled
with the acetylated APTS-coated Fe3O4 NPs decreasedFigure 11 Prussian blue staining of C6 glioma xenografts on the 14th
APTS-coated Fe3O4 NPs (scale bar = 200 μm). (b) A negative PBS control wgradually with time. However, at 21 days following the
intracranial injection of the NP-labeled C6 glioma cells,
the R2 value of the tumor area was significantly higher
than that of the unlabeled tumor area (Figure 10). These
results clearly indicate that acetylated APTS-coated Fe3O4
NPs enable the MR detection of C6 glioma cells both
in vitro and in vivo.
To confirm further the localization of the acetylated
APTS-coated Fe3O4 NPs in the tumor site, the tumor
sections were stained using Prussian blue and observed
using an optical microscope (Figure 11). In the sections
of the NP-labeled xenografted tumors that were isolated
14 days following the injection of the C6 glioma cells,
numerous blue spots were observed to clearly localize in
the cytoplasm of the cells, indicating the presence of the
Fe3O4 NPs (Figure 11a). In contrast, no blue spots were
observed in the negative control (Figure 11b). Our results
suggest that the acetylated APTS-coated Fe3O4 NPs can
be retained in the tumor site for a comparatively long
time, allowing effective MR imaging of tumors.
Conclusions
In summary, we developed a novel type of acetylated
APTS-coated Fe3O4 NPs with a mean diameter of 6.5 nm
for MR imaging both in vitro and in vivo. Combined
morphological observation of cells, MTT assays of cell
viability, and flow cytometric analyses of cell cycle charac-
teristics indicate that acetylated APTS-coated Fe3O4 NPs
do not appreciably affect the cell morphology, viability,
or the cell cycle, indicating their good biocompatibility
at the given concentration range. Furthermore, Prussian
blue staining of cell morphology, TEM imaging, and
ICP-AES quantification data indicate that acetylated
APTS-coated Fe3O4 NPs are able to be taken up by cells
in a concentration-dependent manner. The intracellular
uptake of the particles enables effective MR imaging of
model tumor cells (e.g., C6 glioma cells) in vitro and in
the xenograft tumor model in vivo. Moreover, given theday. (a) The tumor model was labeled with 25 μg/mL of acetylated
ithout particle labeling (scale bar = 200 μm).
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http://www.nanoscalereslett.com/content/9/1/304relatively high transverse relaxivity and the tunable amine
chemistry of APTS-coated Fe3O4 NPs, which can be fur-
ther functionalized with various targeting ligands (e.g.,
folic acid and RGD peptides), it is expected that such NPs
may be further biofunctionalized for various biomedical
applications, especially for targeted MR imaging.
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